Axillary sentinel node biopsy after neoadjuvant chemotherapy

European Journal of Surgical Oncology

Volumn 36, Issue 1, 2010, Pages 23-29

  Ozmen, V ^a   Unal, E S ^a   Muslumanoglu, M E ^a   Igci, A ^a   Canbay, E ^a   Ozcinar, B ^a   Mudun, A ^a   Tunaci, M ^a   Tuzlali, S ^a   Kecer, M ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

False negative rate; Locally advanced breast cancer; Neoadjuvant chemotherapy; Non sentinel lymph node metastasis; Sentinel lymph node biopsy

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; ISOSULFAN BLUE; TECHNETIUM SULFUR COLLOID TC 99M;

ADULT; ADVANCED CANCER; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CYTOPATHOLOGY; DIAGNOSTIC ACCURACY; FALSE NEGATIVE RESULT; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENTINEL LYMPH NODE BIOPSY; TUMOR VOLUME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AXILLA; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FLUOROURACIL; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOADJUVANT THERAPY; SENTINEL LYMPH NODE BIOPSY; TAXOIDS;

EID: 73249122593     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2009.10.015     Document Type: Article

References (30)

1. El Saghir N.S., Eniu A., Carlson R.W., Aziz Z., Vorobiof D., and Hortobagyi G.N. Locally advanced breast cancer: treatment guideline implementation with particular attention to low- and middle-income countries. Cancer 113 (2008) 2315-2324
2. Bonadonna G., Veronesi U., Brambilla C., et al. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 82 (1990) 1539-1545
3. Fisher B., Brown A., Mamounas E., et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15 (1997) 2483-2493
4. Hennessy B.T., Hortobagyi G.N., Rouzier R., et al. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol 23 (2005) 9304-9311
5. Botti C., Vici P., Lopez M., Scinto A.F., Cognetti F., and Cavaliere R. Prognostic value of lymph node metastases after neoadjuvant chemotherapy for large-sized operable carcinoma of the breast. J Am Coll Surg 181 (1995) 202-208
6. Krag D., Weaver D., Ashikaga T., et al. The sentinel node in breast cancer-a multicenter validation study. N Engl J Med 339 (1998) 941-946
7. Breslin T.M., Cohen L., Sahin A., et al. Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer. J Clin Oncol 18 (2000) 3480-3486
8. Nason K.S., Anderson B.O., Byrd D.R., et al. Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma. Cancer 89 (2000) 2187-2194
9. Mamounas E.P., Brown A., Anderson S., et al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 23 (2005) 2694-2702
10. Ozmen V., Karanlik H., Cabioglu N., et al. Factors predicting the sentinel and non-sentinel lymph node metastases in breast cancer. Breast Cancer Res Treat 95 (2006) 1-6
11. Newman E.A., Sabel M.S., Nees A.V., et al. Sentinel lymph node biopsy performed after neoadjuvant chemotherapy is accurate in patients with documented node-positive breast cancer at presentation. Ann Surg Oncol 14 (2007) 2946-2952
12. Fisher B., Wolmark N., Bauer M., Redmond C., and Gebhardt M. The accuracy of clinical nodal staging and of limited axillary dissection as a determinant of histologic nodal status in carcinoma of the breast. Surg Gynecol Obstet 152 (1981) 765-772
13. Davis J.T., Brill Y.M., Simmons S., et al. Ultrasound-guided fine-needle aspiration of clinically negative lymph nodes versus sentinel node mapping in patients at high risk for axillary metastasis. Ann Surg Oncol 13 (2006) 1545-1552
14. Kinoshita T. Sentinel lymph node biopsy is feasible for breast cancer patients after neoadjuvant chemotherapy. Breast Cancer 14 (2007) 10-15
15. Gimbergues P., Abrial C., Durando X., et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy is accurate in breast cancer patients with a clinically negative axillary nodal status at presentation. Ann Surg Oncol 15 (2008) 1316-1321
16. Shen J., Gilcrease M.Z., Babiera G.V., et al. Feasibility and accuracy of sentinel lymph node biopsy after preoperative chemotherapy in breast cancer patients with documented axillary metastases. Cancer 109 (2007) 1255-1263
17. Julian T.B., Dusi D., and Wolmark N. Sentinel node biopsy after neoadjuvant chemotherapy for breast cancer. Am J Surg 184 (2002) 315-317
18. Haid A., Tausch C., Lang A., et al. Is sentinel lymph node biopsy reliable and indicated after preoperative chemotherapy in patients with breast carcinoma?. Cancer 92 (2001) 1080-1084
19. Fernandez A., Cortes M., Benito E., et al. Gamma probe sentinel node localization and biopsy in breast cancer patients treated with a neoadjuvant chemotherapy scheme. Nucl Med Commun 22 (2001) 361-366
20. Borgstein P.J., Pijpers R., Comans E.F., van Diest P.J., Boom R.P., and Meijer S. Sentinel lymph node biopsy in breast cancer: guidelines and pitfalls of lymphoscintigraphy and gamma probe detection. J Am Coll Surg 186 (1998) 275-283
21. Cohen L.F., Breslin T.M., Kuerer H.M., Ross M.I., Hunt K.K., and Sahin A.A. Identification and evaluation of axillary sentinel lymph nodes in patients with breast carcinoma treated with neoadjuvant chemotherapy. Am J Surg Pathol 24 (2000) 1266-1272
22. Tafra L., Lannin D.R., Swanson M.S., et al. Multicenter trial of sentinel node biopsy for breast cancer using both technetium sulfur colloid and isosulfan blue dye. Ann Surg 233 (2001) 51-59
23. O'Hea B.J., Hill A.D., El Shirbiny A.M., et al. Sentinel lymph node biopsy in breast cancer: initial experience at Memorial Sloan-Kettering Cancer Center. J Am Coll Surg 186 (1998) 423-427
24. Stearns V., Ewing C.A., Slack R., Penannen M.F., Hayes D.F., and Tsangaris T.N. Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer. Ann Surg Oncol 9 (2002) 235-242
25. Lenert J.T., Vlastos G., Mirza N.Q., et al. Primary tumor response to induction chemotherapy as a predictor of histological status of axillary nodes in operable breast cancer patients. Ann Surg Oncol 6 (1999) 762-767
26. Rouzier R., Extra J.M., Klijanienko J., et al. Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes. J Clin Oncol 20 (2002) 1304-1310
27. Kuerer H.M., Sahin A.A., Hunt K.K., et al. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Ann Surg 230 (1999) 72-78
28. Jeruss J.S., Newman L.A., Ayers G.D., et al. Factors predicting additional disease in the axilla in patients with positive sentinel lymph nodes after neoadjuvant chemotherapy. Cancer 112 (2008) 2646-2654
29. Tafra L., Verbanac K.M., and Lannin D.R. Preoperative chemotherapy and sentinel lymphadenectomy for breast cancer. Am J Surg 182 (2001) 312-315
30. Schwartz G.F., and Meltzer A.J. Accuracy of axillary sentinel lymph node biopsy following neoadjuvant (induction) chemotherapy for carcinoma of the breast. Breast J 9 (2003) 374-379